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Research on phosphodiesterases both in academic labs and in the pharmaceutical industry has remained
steady over the past 35 years. Although there have been some clinical successes, they have been clustered
around just a couple of PDE isoforms, and disproportionate to the huge investment put forth against what
seem like very druggable targets. This review attempts to uncover the reasons for the lack of productivity
in PDE drug discovery, and summarizes the current hot areas of research. In addition, new insights gath-
ered about structure–function relationships are highlighted, in particular those relating to enzyme regu-
lation. Lastly, novel strategies for targeting the activation or inactivation of selected PDEs are proposed
that may allow for a more targeted approach for PDE modulation.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Phosphodiesterases (PDEs) hydrolyze two of the most impor-
tant signaling molecules in cells, cAMP and cGMP. These important
biomolecules are involved in many signaling processes, particu-
larly those emanating from the extracellular activation of mem-
brane proteins to the internal machinery of the cell. As such,
mammals have evolved intricate systems for controlling localized
intracellular concentrations of these molecules. These systems in-
clude pathways to increase levels through synthesis (via adenylate
cyclase and guanylate cyclase) or to facilitate their disposal either
through hydrolysis by PDEs, or by active transport out of the cell.1
The inhibition of PDEs has remained an active area of drug research
for over thirty years.2 During that time, advances in biology has
identiﬁed additional subtypes, and has enabled a greater under-
standing of the tissue distribution and function of this class of en-
zymes.3,4 There are a total of 21 PDE isoforms grouped into 11
families. The majority of the PDE families (PDE1, 2, 3, 10 and 11)
are dual-substrate and can hydrolize both cAMP and cGMP
although not at similar rates. PDE4, 7 and 8 are cAMP speciﬁc while
PDE5, 6, and 9 only break down cGMP. They differ in their sub-
strate speciﬁcity and afﬁnity, regulatory mechanisms and tissue
distribution.5 To address the ever increasing level of complexity
in the ﬁeld, scientists have developed more powerful tools to aid
in the discovery of potent and subtype-selective agents. These ad-
vances include greater counter-screen capacity as well as struc-
tural information, both experimental and computational, to help
guide inhibitor design.-NC-ND license.Interest in this class of enzymes intensiﬁed after the approval of
sildenaﬁl in 1998, followed closely by vardenaﬁl and tadalaﬁl
(Fig. 1).6 These drugs were moderately selective PDE5 inhibitorsFigure 1. Structures of the ﬁrst three FDA-approved PDE5 inhibitors.
Mg
Figure 2. General mechanism for hydrolysis of cGMP by PDE5 showing some of the key residues involved in the binding of the substrate and the metal ions.
Figure 3. Crystal structures of GMP (yellow) and sildenaﬁl (cyan) bound in the catalytic site of PDE5. (Reprinted from Zhang, K. Y. J. et. al. Mol. Cell, 2004, 15, 279 with
permission from Elsevier.)
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commercial success of these drugs ushered in a new era in PDE re-
search despite the challenging pre-clinical and clinical history of
other PDE targets.
Early research on PDE modulation was non-productive. Selec-
tivity issues were common, often only coming to light after addi-
tional sub-types were discovered. Such endeavors often resulted
in what seemed like intractable issues, such as emesis with PDE4
inhibitors7 or increases in hepatic glucose output in PDE3 blocking
agents;8 two popular early targets. With modern technological ad-
vances, including library synthesis and structure-based design,
achieving selectivity between the PDE families has been shown
to be a difﬁcult but reachable goal.9 Building high levels of selectiv-
ity within a family has proven to be much more challenging. Off
target activities, whether through inhibition of another PDE iso-
form, or by blocking the desired PDE in an undesired tissue, will
continue to hinder progress unless novel strategies are adopted.This review will focus on three areas of contemporary phospho-
diesterase research:
(1) Beyond PDE5: Recent trends in the discovery and develop-
ment of selective catalytic domain inhibitors; (2) new insights into
PDE structure and function; and (3) novel directions for modulat-
ing PDE activity.
The important role of PDEs coupled with the fact that they all
contain a well-deﬁned catalytic site, made these enzymes attrac-
tive targets for intervention in a wide variety of disease states.2 Un-
til very recently, nearly all of the work on these targets involved
blocking the cAMP or cGMP binding site on the catalytic domain.
These catalytic sites contain a base-binding region which positions
the cyclic phosphate group toward the zinc and magnesium ions
which are surrounded by numerous ordered water molecules in-
volved in the hydrolysis step (Fig. 2). Not surprisingly, many PDE
inhibitors resembled the amino purine, or purinone heterocycles
found in the endogenous substrates (Fig. 3), but others bear no
Figure 4. Important PDE4 inhibitors, including roﬂumilast, the only FDA approved
PDE4 inhibitor.
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proved selectivity, at least among the different families. The ap-
proved PDE5 inhibitors shown in Figure 1 exemplify this point
nicely. Both 1 and 2 have purinone-like cores and were poorly
selective over PDE6. Compound 3 is structurally unique with high
selectivity over PDE6.
Despite the successful launch of several PDE5 and PDE3 inhibi-
tors in the late 1990s, extension of this success to other PDE iso-
forms has failed to materialize. The majority of ongoing clinical
trials of PDE inhibitors are not of NCEs but instead are trials of
the already approved PDE5 inhibitors looking at alternative indica-
tions ranging from diabetes to cystic ﬁbrosis.10 In fact, since the
year 2000, the only approved non-PDE5 inhibitor has been roﬂumi-
last (6) in 2011 (Fig. 4). Roﬂumilast is an inhibitor of PDE4 and is
approved for the treatment of respiratory diseases.11 Its approval
came some 35 years after the discovery of the ﬁrst well known
and extensively studied PDE4 inhibitor rolipram (4).12 The devel-
opment challenges of the PDE4 inhibitors are worth reviewing gi-
ven that similar issues have plagued the development of inhibitors
of other PDE isoforms.
PDE4 is a cAMP-speciﬁc PDE with wide tissue distribution and
is considered to be one of the main enzymes responsible forFigure 5. Some of the recently published stcontrolling intracellular cAMP levels. Like many other targets being
pursued in the pharmaceutical industry at the time (i.e., the
1980s), it was believed to be a single enzyme. Based on early re-
search and localization, the two most common diseases targeted
for PDE4 inhibitors were depression and inﬂammation (particu-
larly asthma). The association of PDE4 inhibition and emesis has
been well characterized7 in animals and humans and was one of
the main challenges in their development. An enormous effort
was expended across the pharmaceutical industry to increase the
therapeutic window between efﬁcacy and emetic response. The
strategies were largely empirical, but did include some rational ap-
proaches such as attempting to limit CNS exposure by property-
based design13 (see cilomilast, Fig. 4) and by minimizing systemic
levels of drug by inhalation delivery directly to the lung. Only later
was it discovered that PDE4 is made up of four distinct isoforms, A,
B, C and D. The current thinking is that the anti-inﬂammatory efﬁ-
cacy is mediated through PDE4B whereas the emesis is thought to
be the result of inhibition of PDE4D in the area postrema of the
brain stem via a nor-adrenergic pathway.7 Despite this knowledge,
achieving isoform selectivity within a PDE family has proven to be
extremely challenging, even with the aid of co-crystal structures.
This fact, coupled with the often wide distribution of PDEs meant
that dose-limiting side effects were all too common. To complicate
matters further, each PDE subtype has multiple splice variants, the
roles of which are not well understood (vide infra). All of these fac-
tors complicated the development of PDE inhibitors including rof-
lumilast,14 and despite its eventual approval, its development was
long and expensive only to end up with a somewhat restrictive
label.
One approach to overcome these limitations is to focus on a PDE
family with limited isoforms, and/or limited tissue distribution.
Perhaps by design, or by attrition, the current target receiving
the greatest attention is PDE10. PDE10 fulﬁlls both of these
requirements being a single isoform family, and showing high
expression levels in only a limited number of tissues. It is a dual
substrate PDE hydrolyzing both cAMP and cGMP and its localiza-
tion in the striatum suggested a role in schizophrenia.15 Well over
a dozen companies have ﬁled patents on PDE10 inhibitors over the
past ﬁve years. Some of the published inhibitors are shown in
Figure 5. The Pﬁzer compound, 7,16 is the most advanced, althoughructures of selective PDE10 inhibitors.
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most six years since entering the clinic, it is still in Phase II.10 It is
currently in a trial looking to block the effects of ketamine as eval-
uated by both behavioral and imaging methods. Other inhibitors
have been reported by Schering-Plough17 (nowMerck, 8), Amgen18
(9), Astra-Zeneca19 (10), Wyeth20 (now Pﬁzer, 11) and Lundbeck21
(12).
In addition to PDE10, more modest efforts have appeared for
several other of the more recently identiﬁed PDEs. As a result,
selective inhibitors for PDE7,22–25 PDE826,27 and PDE928–31 are
now available to help further our understanding of these isoforms
(Fig. 6). There is no evidence of any appreciable sub-family selec-
tivity within the disclosed PDE7 and PDE8 inhibitors. PDE9, like
PDE10, has only one isoform.Figure 6. Published structures of inhibitors of some of thePerhaps the most signiﬁcant advances in PDE research occurred
over the past three years and has led to a greater understanding of
the structure–function relationship of the enzymes. Speciﬁcally,
the work unravels the underlying mechanism of how the activity
of certain PDEs are controlled. It has long been known that the
PDE enzymes exist in two domains: a highly conserved catalytic
domain, and a variable regulatory domain.32 A depiction of the
types of regulatory domains of the major PDE families is shown
in Figure 7. The role of these regulatory domains has been an area
of intense research, and as a result, certain aspects of their function
have begun to emerge. For example, the GAF domains, present in
ﬁve of the families, bind cGMP and/or cAMP modulating the activ-
ity of the catalytic domain in an allosteric fashion. Other PDE fam-
ily members have domains that bind to calmodulin (PDE1) or havemore recently discovered PDEs: PDE7, PDE8 and PDE9.
Figure 7. Domains of the eleven PDE families. Catalytic; GAF; Calmodulin binding; Transmembrane (NHR); UCR; PAS; Phosphorylation site.
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play between the enzyme sub-units, for research purposes, the reg-
ulatory domain was truncated; often for screening, and until
recently, universally for structure-based work.
Structure–function studies of the regulatory and catalytic do-
mains progressed largely independently. As mentioned above, they
were dissociated prior to crystallization and most of the early work
focused on the catalytic domain resulting in structures for most of
the 21 isoforms.33 Structures of the regulatory domains, such as
the GAF units are much less common, but have provided important
information about cGMP/cAMP binding sites and residues involved
in dimerization.34–36 Indeed, it appeared that both domains formed
dimers in the solution and crystal states which supported earlier
predictions of dimeric forms of the PDEs based on biochemical
observations.37,38
The tendency for PDEs to dimerize was intriguing. However, the
function of this feature remained elusive until a seminal paper by
Pandit et al in 2009.39 For the ﬁrst time, a near full length crystal
structure of a phosphodiesterase was reported. The structure was
of PDE2A which crystallized as a dimer and contained the GAF-A
and GAF-B subunits of the regulatory domain. The dimer has a long
interface, basically covering the full length of the enzyme. The two
monomers of the dimer cross at the juncture between the two do-
mains forming a structure reminiscent of a pair of scissors (Fig. 8).
Another feature of this structure is that a loop that appears to
block access to the catalytic site in the apo structures of the cata-
lytic domain but swings away freely in ligand-bound structures
(termed the H-loop) is forced into a ‘closed’ state in the dimer
(Fig. 9). This result suggests that dimerization serves to inactivate
the PDE, which upon binding of cGMP to the GAF-B domain, results
in a conformational change at the dimer interface and the H-loop
making the catalytic site accessible. This activation mechanism,
which was proposed by the authors, has yet to be conﬁrmed with
structural data but is in accordance with biochemical observations
(i.e., allosteric regulation with cGMP).
Soon after the PDE2A disclosure, a letter describing the regula-
tion of PDE4D was published also based on crystallographic evi-
dence.40 In this instance, the regulatory domain has a much more
direct role in controlling function by physically blocking access
to the catalytic site. The conformational changes involved are inpart controlled by phosphorylation of the UCR (Upstream Con-
served Region) domain. Such mechanisms reveal alternative strat-
egies for the inactivation or even activation of various PDEs and
will be discussed in the last section of this review.
Phosphodiesterases are ancient proteins from an evolutionary
perspective. They play a key role in modulating two of the most
important signaling molecules in cells. But despite major advances
in our understanding of these enzymes and their roles in certain
disease states, clinical and commercial success beyond PDE5 has
been disappointing. Perhaps this outcome is in part due to the
enormous complexity of the PDE systems that has emerged in re-
cent years. Fundamental to this challenge is the interplay between
the roles of multiple isoforms and splice variants within a single
cell. To reconcile the apparent redundancies among the PDEs one
must conclude that the cells possess the ability to carefully control
the expression, regulation, dimerization and compartmentalization
of various PDEs in a manner that is beyond our complete under-
standing. It is likely that it is from this new frontier that the next
generation of PDE therapeutics will emerge. The days of simply
shutting down activity of the catalytic site and hoping for the best
appear numbered.
As mentioned earlier, the expression of most PDEs is far too
extensive not to expect some off-tissue or off-target side effects
that will become dose-limiting in clinical trials. This challenge is
particularly relevant when the therapies are targeting cardiovascu-
lar, metabolic and CNS diseases where safety is paramount. In or-
der to more selectively and safely modulate cAMP or cGMP
levels, a greater understanding of the particular PDE isoform, splice
variant, and localization in the disease tissue of interest is required.
Careful study of this protein may also provide insights about its
regulation as well as any associated proteins which may control
its function or compartmentalization. This information, although
daunting, could provide many additional opportunities for inter-
vention beyond the catalytic site. Possibilities include interfering
with enzyme dimerization, inhibiting phosphorylation, or blocking
the activation of the catalytic domain induced by allosteric binding
of cAMP or cGMP to the regulatory domain.
Sufﬁcient details have already emerged for selected PDEs to
support such strategies. Enzyme splice variants for example, which
are alternative combinations of exons, have largely been ignored in
Figure 8. Crystal structure of a nearly full length construct of PDE2A showing a
dimeric structure. One monomer is displayed as a surface representation while the
second one is in ribbon format. (Reprinted with permission from: Pandit, J.; Forman,
M. D.; Fennell, K. F.; Dillman, K. S.; Menniti, F. S. Proc. Natl. Acad. Sci. U.S.A., 2009,
106, 18225.)
Figure 9. Proposed mechanism for activation of dimeric PDE2A upon cGMP binding
to the GAF domain.39
Figure 10. Structures of PDE4D and PDE5 allosteric modulators.
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variants were overlooked despite data suggesting that these
post-transcriptional modiﬁcations are not just accidents of nature
but seem to play a role in the compartmentalization and regulation
of speciﬁc PDE isoforms.41 Not unexpectedly, all of these modiﬁca-
tions occur in the regulatory domains of the proteins. PDE9, which
consists of over 20 splice variants, includes at least one which was
shown to be localized to the nucleus.42,43 Its role there is not yet
clear. In addition, variants of PDE4D have been shown to be differ-
entially expressed in various tissues in the rat.44
Efforts focusing on non-traditional strategies for PDE modula-
tion have already begun to appear in the literature. A group from
deCODE Genetics has optimized a series of allosteric PDE4D partial
inhibitors such as D159687 which show cognition enhancing ef-
fects and reduced potential for emesis. (Fig. 10). The compounds
bind at the interface of the catalytic site and the UCR2 unit of the
regulatory domain.40 Researchers at the University of Tübingenspeciﬁcally targeted the cGMP allosteric binding sites on the
GAF domains of PDE5.45 For the HTS screen, the GAF-A and GAF-
B domains were coupled to adenylate cyclase. Hits such as
NYC118277 and NYC292005 were identiﬁed, and although not
very attractive starting points, do show the validity of the ap-
proach. They are now attempting to co-crystalize these compounds
with the GAF proteins.
It is appreciated that targeting increased speciﬁcity runs
contrary to some of the contemporary ideas of drug discovery. Phe-
notypic screening has gained in popularity in recent years as a way
to improve efﬁcacy by targeting multiple pathways with a single
agent.46,47 However, the case for PDEs is somewhat unique given
the ubiquitous nature of the signaling molecules they regulate.
As such, a more targeted approach toward regulating their activity
may prove more successful in the end.
In summary, phosphodiesterases have been shown to be fasci-
nating enzymes. Current approaches for modulating their activity
through inhibition of the catalytic site have not been productive
despite evidence for their role in certain disease states. New infor-
mation regarding the structure and function of the individual PDE
isoforms, in combination with novel insights about their expres-
sion, localization and regulation provide abundant opportunities
for the next generation of PDE modulating drugs.
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